MENU
TRIDENT Investigators Meeting was held on the 18th of October 2025, Colombo, marking the completion of this impactful 7-year global neurological study.
Led by The George Institute for Global Health, TRIDENT is the first stroke outcomes trial using a single-pill triple therapy (GMRx2) for blood pressure management in adults with prior intracerebral hemorrhage (ICH).
TRIDENT is a multicenter, international, double-blind, placebo-controlled, parallel-group, randomized controlled trial in patients with a history of ICH designed to evaluate the effect of GMRx2 (telmisartan 20 mg/ amlodipine 2.5mg/ indapamide 1.25mg), compared with placebo, given once daily in addition to standard of care. The safety findings for GMRx2 in the TRIDENT trial were consistent with the known safety profile of the medicine and its individual components.
TRIDENT study was conducted across multiple countries including Australia, Brazil, Georgia, Malaysia, Nigeria, The Netherlands, Singapore, Sri Lanka, Taiwan, and the United Kingdom, the study represents a major global effort to address unmet needs in stroke prevention. Sri Lanka played a vital role in this global effort — 1,114 patients from 7 hospitals across the country were enrolled in the study, demonstrating the strength and dedication of our local investigators, trial centers, and participants. The principal coordinator for Sri Lanka was Dr Bimsara Senanayake, Consultant Neurologist from National Hospital of Sri Lanka.
The trial results were presented at the World Stroke Congress 2025 in Barcelona, highlighting the impact of international collaboration and innovation to transform outcomes for stroke survivors worldwide.
A sincere thank you to all investigators, trial centers, partners, and participants whose dedication made this achievement possible.
Stay tuned for the official release of the upcoming TRIDENT results.